An ltbr agonist in combination therapy against cancer

The present invention relates to a combination comprising a Treg depletor and an LTBR agonist. Such a combination is particularly useful for use in the treatment of a cancer. Exemplified is the generation of mouse antagonist CCR8 VHH and of CCR8 VHH-Fc fusions as well as the generations of LTBR agonistic single domain antibodies. One anti-CCR8 antibody VHH-Fc and one LTBR agonist VHH have been tested in an MC38 syngeneic mouse model and shown to allow 100% of the tested mice to survive after 25 days, versus 60% with the VHH binding LTBR and 70% with the VHH- Fc binding CCR8. Also exemplified is the effect of a combination of an anti-CTLA4 antibody and a LTBR agonist (VHH-16) on tumor growth im an MC38 syngeneic mouse model resulting in synergism in reducing tumor burden.

Patent Publication Number: EP4255929

Year filing: 2021

Year approval: 2024

Year publication: 2023

Status: Requested

Technology domains: undefined

Validated for IOF-key: Yes

Attributed to: Associatie KULeuven, Universitaire Associatie Brussel